Hwail Pharmaceutical Co., Ltd.
KKRX:0612505,920.00
KRW
-100.00
(-1.66%)
ISIN
KR7061250007
Return %
Stock
S&P 500
1Y
-47.66
14.39
3Y
-69.34
81.42
5Y
-80.17
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 145
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Pyeongtaek-si South Korea
- IPO Date
- Apr 18, 2002
- Website
- hwail.com
- Similar Companies
- Business
- Hwail Pharmaceutical Co., Ltd. is a South Korea-based pharmaceutical manufacturing company primarily engaged in the research, development, production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage pharmaceuticals, and functional health food ingredients. Founded in 1980 and headquartered in Hwaseong-si, Gyeonggi-do, South Korea, the company operates Good Manufacturing Practice (GMP)-compliant chemical synthesis and finished drug production facilities, supplying healthcare institutions, generic drug manufacturers, and life sciences corporations across South Korea, Japan, Southeast Asia, and broader international markets. The company operates through specialized business segments encompassing Active Pharmaceutical Ingredients, Finished Pharmaceuticals, and Healthcare & Nutritional Materials. Its core product and service portfolio includes: respiratory system treatments, featuring mucolytic and bronchodilator APIs such as erdosteine and acebrophylline; cardiovascular and circulatory agents, including antihypertensive and antithrombotic compounds; gastrointestinal therapies and digestive tract regulators; anti-inflammatory analgesics and musculoskeletal disorder medications; anti-infectives, antifungals, and antibiotic intermediates; antihistamines, central nervous system agents, and metabolic disease treatments; functional nutritional ingredients and raw materials for dietary supplements; and comprehensive contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services spanning custom chemical synthesis, formulation research, regulatory documentation support, and commercial batch manufacturing. In recent strategic developments, Hwail Pharmaceutical has diversified its advanced therapeutic pipeline by entering the pharmaceutical-grade cannabinoid sector, establishing collaborative research initiatives and supply arrangements with biotechnology ventures and academic research centers to develop non-narcotic cannabidiol (CBD) and cannabinoid-based APIs for neurodegenerative conditions, epilepsy, and rare diseases. The company has also executed substantial facility upgrades and automation enhancements at its Hyangnam synthesis plant to strengthen cGMP compliance, expand high-purity API synthesis capacity, and meet growing regulatory standards for global export expansion. In addition, following strategic shareholding and board restructuring initiatives, Hwail Pharmaceutical has reinforced its commercial alliances and co-promotion agreements with major domestic pharmaceutical partners to scale domestic distribution of high-demand respiratory treatments and expand export penetration across Asian and European generic drug markets.